Tuberous sclerosis

The Lancet

Volumn 372, Issue 9639, 2008, Pages 657-668

  Curatolo, Paolo ^a   Bombardieri, Roberta ^a   Jozwiak, Sergiusz ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; TUBERIN;

CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; COMPLEX FORMATION; DISEASE SEVERITY; EARLY DIAGNOSIS; GENE; HAMARTOMA; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RELATIVE; REVIEW; SYMPTOMATOLOGY; SYSTEMIC DISEASE; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

EID: 49649118165     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61279-9     Document Type: Review

References (159)

1. Gomez M.R., Sampson J.R., and Whittemore V.H. Tuberous sclerosis complex. 3rd edn. (1999), Oxford University Press, New York
2. Curatolo P. Tuberous sclerosis complex: from basic science to clinical phenotypes (2003), Mac Keith Press for the International Child Neurology Association, London
3. Bourneville D.M. Sclérose tubéreuse des circonvolutions cérébrales. Arch Neurol 1 (1880) 81-91
4. Moolten S.E. Hamartial nature of the tuberous sclerosis complex and its bearing on the tumour problem: report of one case with tumour anomaly of the kidney and adenoma sebaceum. Arch Intern Med 69 (1942) 589-623
5. Lagos J.C., and Gomez M.R. Tuberous sclerosis: reappraisal of a clinical entity. Mayo Clin Proc 42 (1967) 26-49
6. Smythe J.F., Dyck J.D., Smallhorn J.F., and Freedom R.M. Natural history of cardiac rhabdomyoma in infancy and childhood. Am J Cardiol 66 (1990) 1247-1249
7. Roach E.S., Gomez M.R., and Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 13 (1998) 624-628
8. O'Callaghan F.J., Shiell A.W., Osborne J.P., and Martyn C.N. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 351 (1998) 1490
9. Webb D.W., Thomas R.D., and Osborne J.P. Cardiac rhabdomyomas and their association with tuberous sclerosis. Arch Dis Child 68 (1993) 367-370
10. Osborne J.P., Fryer A., and Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 615 (1991) 125-127
11. Fryer A.E., Chalmers A., Connor J.M., et al. Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet 1 (1987) 659-661
12. Kandt R.S., Haines J.L., Smith M., et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet 2 (1992) 37-41
13. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277 (1997) 805-808
14. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75 (1993) 1305-1315
15. Dabora S.L., Jozwiak S., Franz D.N., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68 (2001) 64-80
16. Jones A.C., Shyamsundar M.M., Thomas M.W., et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64 (1999) 1305-1315
17. Choi J.E., Chae J.H., Hwang Y.S., and Kim K.J. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex. Brain Dev 28 (2006) 440-446
18. Hung C.C., Su Y.N., Chien S.C., Lio, et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet 7 (2006) 72
19. Langkau N., Martin N., Brandt R., et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/TSC2 frequency ratios. Eur J Pediatr 161 (2002) 393-402
20. Sancak O., Nellist M., Goedbloed M., et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 13 (2005) 731-741
21. Au K.S., Williams A.T., Roach E.S., et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 9 (2007) 88-100
22. Kozlowski P., Roberts P., Dabora S., et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121 (2007) 389-400
23. Sampson J.R., Maheshwar M.M., Aspinwall R., et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 61 (1997) 843-851
24. Maheshwar M.M., Cheadle J.P., Jones A.C., et al. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet 6 (1997) 1991-1996
25. Kwiatkowska J., Wigowska-Sowinska J., Napierala D., Slomski R., and Kwiatkowski D.J. Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med 340 (1999) 703-707
26. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., and Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99 (2002) 13571-13576
27. Gao X., Zhang Y., Arrazola P., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4 (2002) 699-704
28. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
29. Astrinidis A., and Henske E.P. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24 (2005) 7475-7481
30. Kwiatkowski D.J., and Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 (2005) R251-R258
31. Marcotte L., and Crino P.B. The neurobiology of the tuberous sclerosis complex. Neuromolecular Med 8 (2006) 531-546
32. Brugarolas J., Lei K., Hurley R.L., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18 (2004) 2893-2904
33. Ellisen L.W. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 4 (2005) 1500-1502
34. Jozwiak J., Jozwiak S., Grzela T., and Lazarczyk M. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med 7 (2005) 287-296
35. Yates J.R. Tuberous sclerosis. Eur J Hum Genet 14 (2006) 1065-1073
36. Chan J.A., Zhang H., Roberts P.S., et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63 (2004) 1236-1242
37. Henske E.P., Wessner L.L., Golden J., et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151 (1997) 1639-1647
38. Carbonara C., Longa L., Grosso E., et al. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 15 (1996) 18-25
39. Karbowniczek M., Astrinidis A., Balsara B.R., et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167 (2003) 976-982
40. Crino P.B., Nathanson K.L., and Henske E.P. The tuberous sclerosis complex. N Engl J Med 355 (2006) 1345-1356
41. Lamb R.F., Roy C., Diefenbach T.J., et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2 (2000) 281-287
42. Astrinidis A., Cash T.P., Hunter D.S., Walker C.L., Chernoff J., and Henske E.P. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21 (2002) 8470-8476
43. Rok P., Kasprzyk-Obara J., Domanska-Pakiela D., and Jozwiak S. Clinical symptoms of tuberous sclerosis complex in patients with an identical TSC2 mutation. Med Sci Monit 11 (2005) CR230-CR234
44. Devlin L.A., Shepherd C.H., Crawford H., and Morrison P.J. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol 48 (2006) 495-499
45. Lendvay T.S., and Marshall F.F. The tuberous sclerosis complex and its highly variable manifestations. J Urol 169 (2003) 1635-1642
46. Khare L., Strizheva G.D., Bailey J.N., et al. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J Med Genet 38 (2001) 347-349
47. Jansen A.C., Sancak O., D'Agostino M.D., et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol 60 (2006) 528-539
48. Mayer K., Goedbloed M., van Zijl K., Nellist M., and Rott H.D. Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis. J Med Genet 41 (2004) e64
49. Connor J.M., Stephenson J.B., and Hadley M.D. Non-penetrance in tuberous sclerosis. Lancet 2 (1986) 1275
50. Dabora S.L., Roberts P., Nieto A., et al. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 71 (2002) 750-758
51. Curatolo P., Cusmai R., Cortesi F., Chiron C., Jambaque I., and Dulac O. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci 615 (1991) 8-16
52. DiMario Jr. F.J. Brain abnormalities in tuberous sclerosis complex. J Child Neurol 19 (2004) 650-657
53. Luat A.F., Makki M., and Chugani H.T. Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol 20 (2007) 142-150
54. Jurkiewicz E., and Jozwiak S. Giant intracranial aneurysm in a 9-year-old boy with tuberous sclerosis. Pediatr Radiol 36 (2006) 463
55. Ridler K., Bullmore E.T., De Vries P.J., et al. Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis. Psychol Med 31 (2001) 1437-1446
56. Curatolo P., and Brinchi V. Antenatal diagnosis of tuberous sclerosis. Lancet 341 (1993) 176-177
57. Khanna P.C., Godinho S., Pungavkar S.A., and Patkar D.P. Ultrafast MRI in the prenatal diagnosis of Bourneville's tuberous sclerosis. Neurol India 53 (2005) 349-350
58. Calcagnotto M.E., Paredes M.F., Tihan T., Barbaro N.M., and Baraban S.C. Dysfunction of synaptic inhibition in epilepsy associated with focal cortical dysplasia. J Neurosci 25 (2005) 9649-9657
59. Nabbout R., Santos M., Rolland Y., Delalande O., Dulac O., and Chiron C. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66 (1999) 370-375
60. Goh S., Butler W., and Thiele E.A. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63 (2004) 1457-1461
61. O'Callaghan F.J. Prevalence of subependymal giant cells astrocytomas in TSC patients in th Wessex Region. J Child Neurol 16 (2001) 678
62. Torres O.A., Roach E.S., Delgado M.R., et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 13 (1998) 173-177
63. Raju G.P., Urion D.K., and Sahin M. Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol 36 (2007) 128-131
64. Curatolo P., Seri S., Verdecchia M., and Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev 23 (2001) 502-507
65. Curatolo P., Verdecchia M., and Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol 6 (2002) 15-23
66. Seri S., Cerquiglini A., Pisani F., Michel C.M., Marqui R.P., and Curatolo P. Frontal lobe epilepsy associated with tuberous sclerosis: electroencephalographic-magnetic resonance image fusioning. J Child Neurol 13 (1998) 33-38
67. Cusmai R., Chiron C., Curatolo P., Dulac O., and Tran-Dinh S. Topographic comparative study of magnetic resonance imaging and electroencephalography in 34 children with tuberous sclerosis. Epilepsia 31 (1990) 747-755
68. Jansen F.E., van Huffelen A.C., Bourez-Swart M., and van Nieuwenhuizen O. Consistent localization of interictal epileptiform activity on EEGs of patients with tuberous sclerosis complex. Epilepsia 46 (2005) 415-419
69. White R., Hua Y., Scheithauer B., Lynch D.R., Henske E.P., and Crino P.B. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann Neurol 49 (2001) 67-78
70. Valencia I., Legido A., Yelin K., Khurana D., Kothare S.V., and Katsetos C.D. Anomalous inhibitory circuits in cortical tubers of human tuberous sclerosis complex associated with refractory epilepsy: aberrant expression of parvalbumin and calbindin-D28k in dysplastic cortex. J Child Neurol 21 (2006) 1058-1063
71. Wang Y., Greenwood J.S., Calcagnotto M.E., Kirsch H.E., Barbaro N.M., and Baraban S.C. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol 61 (2007) 139-152
72. Jansen L.A., Uhlmann E.J., Crino P.B., Gutmann D.H., and Wong M. Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. Epilepsia 46 (2005) 1871-1880
73. Chiron C., Dulac O., Luna D., et al. Vigabatrin in infantile spasms. Lancet 335 (1990) 363-364
74. Curatolo P., Verdecchia M., and Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 23 (2001) 649-653
75. Hancock E., and Osborne J.P. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 14 (1999) 71-74
76. Jambaque I., Chiron C., Dumas C., Mumford J., and Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 38 (2000) 151-160
77. Lortie A., Plouin P., Chiron C., Delalande O., and Dulac O. Characteristics of epilepsy in focal cortical dysplasia in infancy. Epilepsy Res 51 (2002) 133-145
78. Curatolo P., Bombardieri R., and Cerminara C. Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neurol 19 (2006) 119-123
79. Wild J.M., Robson C.R., Jones A.L., Cunliffe I.A., and Smith P.E. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47 (2006) 917-924
80. Parisi P., Bombardieri R., and Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol 11 (2007) 331-336
81. Harding G.F., Wild J.M., Robertson K.A., et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 41 (2000) 1420-1431
82. Harding G.F., Wild J.M., Robertson K.A., Rietbrock S., and Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 55 (2000) 347-352
83. Harding G.F., Spencer E.L., Wild J.M., Conway M., and Bohn R.L. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 58 (2002) 1261-1265
84. de Vries P.J., Hunt A., and Bolton P.F. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 16 (2007) 16-24
85. Prather P., and de Vries P.J. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 19 (2004) 666-674
86. Joinson C., O'Callaghan F.J., Osborne J.P., Martyn C., Harris T., and Bolton P.F. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 33 (2003) 335-344
87. Harrison J.E., O'Callaghan F.J., Hancock E., Osborne J.P., and Bolton P.F. Cognitive deficits in normally intelligent patients with tuberous sclerosis. Am J Med Genet 88 (1999) 642-646
88. Jambaque I., Cusmai R., Curatolo P., Cortesi F., Perrot C., and Dulac O. Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Dev Med Child Neurol 33 (1991) 698-705
89. Raznahan A., Higgins N.P., Griffiths P.D., Humphrey A., Yates J.R., and Bolton P.F. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med 37 (2007) 1293-1304
90. Humphrey A., Higgins J.N., Yates J.R., and Bolton P.F. Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits. Neurology 62 (2004) 795-798
91. Deonna T., Roulet-Perez E., Chappuis H., and Ziegler A.L. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev Med Child Neurol 49 (2007) 320
92. Humphrey A., Neville B.G., Clarke A., and Bolton P.F. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev Med Child Neurol 48 (2006) 609-611
93. Curatolo P., Porfirio M.C., Manzi B., and Seri S. Autism in tuberous sclerosis. Eur J Paediatr Neurol 8 (2004) 327-332
94. Bruni O., Cortesi F., Giannotti F., and Curatolo P. Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain Dev 17 (1995) 52-56
95. Jozwiak S., Schwartz R.A., Janniger C.K., and Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 15 (2000) 652-659
96. Webb D.W., Fryer A.E., and Osborne J.P. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 38 (1996) 146-155
97. Webb D.W., Clarke A., Fryer A., and Osborne J.P. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 135 (1996) 1-5
98. Hall M.R., Kovach B.T., and Miller J.L. Unilateral facial angiofibromas without other evidence of tuberous sclerosis: case report and review of the literature. Cutis 80 (2007) 284-288
99. Jozwiak S., Schwartz R.A., Janniger C.K., Michalowicz R., and Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 37 (1998) 911-917
100. Flanagan N., O'Connor W.J., McCartan B., Miller S., McMenamin J., and Watson R. Developmental enamel defects in tuberous sclerosis: a clinical genetic marker?. J Med Genet 34 (1997) 637-639
101. Bader R.S., Chitayat D., Kelly E., et al. Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 143 (2003) 620-624
102. Jozwiak S., Kotulska K., Kasprzyk-Obara J., et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics 118 (2006) e1146-e1151
103. Shepherd C.W., Gomez M.R., Lie J.T., and Crowson C.S. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66 (1991) 792-796
104. O'Callaghan F.J., Noakes M.J., Martyn C.N., and Osborne J.P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94 (2004) 853-857
105. Rakowski S.K., Winterkorn E.B., Paul E., Steele D.J., Halpern E.F., and Thiele E.A. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70 (2006) 1777-1782
106. Ewalt D.H., Sheffield E., Sparagana S.P., Delgado M.R., and Roach E.S. Renal lesion growth in children with tuberous sclerosis complex. J Urol 160 (1998) 141-145
107. Ewalt D.H., Diamond N., Rees C., et al. Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 174 (2005) 1764-1766
108. Williams J.M., Racadio J.M., Johnson N.D., Donnelly L.F., and Bissler J.J. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis 47 (2006) 95-102
109. Winterkorn E.B., Daouk G.H., Anupindi S., and Thiele E.A. Tuberous sclerosis complex and renal angiomyolipoma: case report and review of the literature. Pediatr Nephrol 21 (2006) 1189-1193
110. Kothary N., Soulen M.C., Clark T.W., et al. Renal angiomyolipoma: long-term results after arterial embolization. J Vasc Interv Radiol 16 (2005) 45-50
111. Simmons J.L., Hussain S.A., Riley P., and Wallace D.M. Management of renal angiomyolipoma in patients with tuberous sclerosis complex. Oncol Rep 10 (2003) 237-241
112. Washecka R., and Hanna M. Malignant renal tumors in tuberous sclerosis. Urology 37 (1991) 340-343
113. Robertson F.M., Cendron M., Klauber G.T., and Harris B.H. Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg 31 (1996) 729-730
114. Bjornsson J., Short M.P., Kwiatkowski D.J., and Henske E.P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149 (1996) 1201-1208
115. Rowley S.A., O'Callaghan F.J., and Osborne J.P. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol 85 (2001) 420-423
116. Shami M.J., Benedict W.L., and Myers M. Early manifestation of retinal hamartomas in tuberous sclerosis. Am J Ophthalmol 115 (1993) 539-540
117. Robertson D.M. Ophthalmic manifestations of tuberous sclerosis. Ann N Y Acad Sci 615 (1991) 17-25
118. Mennel S., Meyer C.H., Peter S., Schmidt J.C., and Kroll P. Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand 85 (2007) 127-132
119. Hancock E., and Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 96 (2002) 1-6
120. Miyake M., Tateishi U., Maeda T., et al. Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat Med 23 (2005) 525-527
121. Aubry M.C., Myers J.L., Ryu J.H., et al. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 162 (2000) 749-752
122. McCormack F.X., and Moss J. S-LAM in a man?. Am J Respir Crit Care Med 176 (2007) 3-5
123. Sato T., Seyama K., Fujii H., et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47 (2002) 20-28
124. Smolarek T.A., Wessner L.L., McCormack F.X., Mylet J.C., Menon A.G., and Henske E.P. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62 (1998) 810-815
125. Carsillo T., Astrinidis A., and Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97 (2000) 6085-6090
126. Avila N.A., Dwyer A.J., Rabel A., and Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 242 (2007) 277-285
127. Finlay G.A., York B., Karas R.H., et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J Biol Chem 279 (2004) 23114-23122
128. Fleury P., Smits N., and van Baal S. The incidence of hepatic hamartomas in tuberous sclerosis. Evaluation by ultrasonography. Rofo 146 (1987) 694-696
129. Jozwiak S., Pedich M., Rajszys P., and Michalowicz R. Incidence of hepatic hamartomas in tuberous sclerosis. Arch Dis Child 67 (1992) 1363-1365
130. Jozwiak S., Michalowicz R., Pedich M., and Rajszys P. Hepatic hamartoma in tuberous sclerosis. Lancet 339 (1992) 180
131. Shepherd C.W., Beard C.M., Gomez M.R., Kurland L.T., and Whisnant J.P. Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989. Arch Neurol 48 (1991) 400-401
132. Jozwiak S., Kawalec W., Dluzewska J., Daszkowska J., Mirkowicz-Malek M., and Michalowicz R. Cardiac tumours in tuberous sclerosis: their incidence and course. Eur J Pediatr 153 (1994) 155-157
133. DiMario Jr. F.J., Diana D., Leopold H., and Chameides L. Evolution of cardiac rhabdomyoma in tuberous sclerosis complex. Clin Pediatr 35 (1996) 615-619
134. de Vries P., Humphrey A., McCartney D., Prather P., Bolton P., and Hunt A. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in tuberous sclerosis. Eur Child Adolesc Psychiatry 14 (2005) 183-190
135. Jozwiak S., Domanska-Pakiela D., Kwiatkowski D.J., and Kotulska K. Multiple cardiac rhabdomyomas as a sole symptom of tuberous sclerosis complex: case report with molecular confirmation. J Child Neurol 20 (2005) 988-989
136. Sampson J.R., Scahill S.J., Stephenson J.B., Mann L., and Connor J.M. Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet 26 (1989) 28-31
137. de Ribaupierre S., Dorfmuller G., Bulteau C., et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?. Neurosurgery 60 (2007) 83-89
138. Curatolo P., Bombardieri R., Verdecchia M., and Seri S. Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol 20 (2005) 318-325
139. Sparagana S.P., Delgado M.R., Batchelor L.L., and Roach E.S. Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Arch Neurol 60 (2003) 1286-1289
140. Jansen F.E., van Huffelen A.C., Algra A., and van Nieuwenhuizen O. Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 48 (2007) 1477-1484
141. 11C]methyl-L-tryptophan positron emission tomography. Ann Neurol 44 (1998) 858-866
142. Jansen F.E., Braun K.P., van Nieuwenhuizen O., et al. Diffusion-weighted magnetic resonance imaging and identification of the epileptogenic tuber in patients with tuberous sclerosis. Arch Neurol 60 (2003) 1580-1584
143. Peresson M., Lopez L., Narici L., and Curatolo P. Magnetic source imaging and reactivity to rhythmical stimulation in tuberous sclerosis. Brain Dev 20 (1998) 512-518
144. Jansen F.E., Huiskamp G., van Huffelen A.C., et al. Identification of the epileptogenic tuber in patients with tuberous sclerosis: a comparison of high-resolution EEG and MEG. Epilepsia 47 (2006) 108-114
145. Wu J.Y., Sutherling W.W., Koh S., et al. Magnetic source imaging localizes epileptogenic zone in children with tuberous sclerosis complex. Neurology 66 (2006) 1270-1272
146. Zaroff C.M., Morrison C., Ferraris N., Weiner H.L., Miles D.K., and Devinsky O. Developmental outcome of epilepsy surgery in tuberous sclerosis complex. Epileptic Disord 7 (2005) 321-326
147. Weiner H.L., Ferraris N., LaJoie J., Miles D., and Devinsky O. Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol 19 (2004) 687-689
148. Roach E.S., DiMario F.J., Kandt R.S., and Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14 (1999) 401-407
149. Jozwiak J., Jozwiak S., and Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 26 (2006) 160-180
150. Kaur S., Lal L., Sassano A., et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 282 (2007) 1757-1768
151. Rauktys A., Lee N., Lee L., and Dabora S.L. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 8 (2008) 1
152. Goncharova E.A., Goncharov D.A., Lim P.N., Noonan D., and Krymskaya V.P. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 34 (2006) 473-480
153. Lee L., Sudentas P., and Dabora S.L. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 45 (2006) 933-944
154. Robb V.A., Karbowniczek M., Klein-Szanto A.J., and Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177 (2007) 34-52
155. Weimbs T. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?. Cell Cycle 5 (2006) 2425-2429
156. Herry I., Neukirch C., Debray M.P., Mignon F., and Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18 (2007) 76-77
157. Wienecke R., Fackler I., Linsenmaier U., Mayer K., Licht T., and Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48 (2006) e27-e29
158. Franz D.N., Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59 (2006) 490-498
159. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 (2008) 140-151